[36] Net cash flows from investing activities Audited

A total of EUR 4,859.7 million was used for acquisitions and investments in other financial assets (2009: EUR 40.0 million). Of this amount, EUR 4,843.7 million (2009: EUR 23.5 million) was used for acquisitions. Investments in other financial assets totaled EUR 16.0 million (2009: EUR 16.5 million). Taking into consideration cash included in the acquisition, the payment of the Millipore purchase price involved cash outflows of EUR 4,837.1 million. A final payment of EUR 6.6 million was made for the Suzhou Taizhu China Group, which was acquired in 2009.

The divestment of Théramex did not result in any cash inflows in 2010 since the purchase price payment was made in January 2011. Cash outflows within the scope of this divestment amounted to EUR 9.7 million. These comprised cash and cash equivalents of Théramex totaling EUR 9.2 million on the date of deconsolidation as well as transaction costs of EUR 0.5 million. This is disclosed in the cash flow statement under “Disposal of non-current assets”. Net cash inflows from changes in other financial assets amounting to EUR 1,431.3 million were mainly the result of the sale of short-term securities and financial assets and were used to finance the acquisition of Millipore.